№ files_lp_3_process_7_039140
File format: docx
Character count: 65727
File size: 99 KB
Collection of sacred Bahá’í tablets and devotional passages attributed to Bahá’u’lláh, including exhortations, theological reflections, and a tablet of visitation within the framework of successive divine revelations.
Year:
2025
Author:
Bahá’u’lláh
Religious Tradition:
Bahá’í Faith
Genre:
Sacred scripture
Form:
Tablets and devotional texts
Primary Themes:
Revelation, divine love, steadfastness, martyrdom, spiritual transformation
Named Individuals:
Muḥammad-‘Alí
Liturgical Element:
Tablet of visitation
Language Style:
Devotional and exhortatory prose
Intended Audience:
Believers and followers of the Cause of God
Historical Context:
Successive divine dispensations and fulfillment of prophetic promises
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
1981
Revision:
1990
Region / city:
Haifa, Wilmette
Subject:
Spiritual guidance, divine assistance, Bahá’í Faith
Document type:
Compilation of religious texts
Institution:
Universal House of Justice
Author:
Bahá’u’lláh, the Báb
Target audience:
Followers of the Bahá’í Faith and general readership interested in Bahá’í writings
Sources cited:
Gleanings from the Writings of Bahá’u’lláh, Tablets of Bahá’u’lláh, The Advent of Divine Justice, The World Order of Bahá’u’lláh
Content focus:
Divine support, spiritual empowerment, steadfastness in faith, moral and spiritual teachings
Period covered:
Various periods within the Bahá’í Revelation, compiled 1981, revised 1990
Religion:
Bahá’í Faith
Genre:
Devotional literature
Type of document:
Prayer collection
Authors:
Bahá’u’lláh; the Báb; ‘Abdu’l-Bahá
Compiler / editorial authority:
Bahá’í community publications
Language:
English
Core sections:
Obligatory Prayers; General Prayers; Occasional Prayers; Special Tablets
Key topics:
worship; devotion; spiritual growth; unity; healing; teaching the Faith
Included prayers:
Short Obligatory Prayer; Medium Obligatory Prayer; Long Obligatory Prayer
Associated places mentioned:
Bahjí, ‘Akká
Intended audience:
adherents of the Bahá’í Faith and participants in devotional practice
Year:
1995
Date:
February 1995
Subject:
Bahá’í scholarship, knowledge, education and the role of scholars
Document type:
Compilation of extracts from religious writings and letters
Prepared by:
Research Department of the Universal House of Justice
Organization:
Universal House of Justice
Religious tradition:
Bahá’í Faith
Primary authors cited:
Bahá’u’lláh; ‘Abdu’l-Bahá; Shoghi Effendi; Universal House of Justice
Source texts:
Tablets of Bahá’u’lláh Revealed after the Kitáb-i-Aqdas; The Kitáb-i-Aqdas; The Promulgation of Universal Peace; letters written on behalf of Shoghi Effendi
Structure:
The Station of Scholarship; Functions of Bahá’í Scholarship; General Principles and Guidelines
Topics covered:
importance of knowledge and learning, characteristics of the truly learned, scope of Bahá’í scholarship, promotion of human welfare, defence of the Faith, scholarly methodology, spiritual foundations of learning
Year:
1919
Region:
Haifa, Palestine
Subject:
Religious prayers and meditations
Document type:
Book
Author:
Bahá’u’lláh
Translator:
Shoghi Effendi
Language style:
Classical English
Number of prayers:
137
Period covered:
Various periods of Bahá’u’lláh’s life
Format:
Text compilation of prayers
Year:
2023
Region / city:
Leipzig, Hannover
Topic:
Neuroimaging, Iron Homeostasis, Dopaminergic System, Tourette Syndrome
Document type:
Research Paper
Organization / institution:
Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig University, Hannover Medical School
Authors:
Dimitrios G. Gkotsoulias, Michael Rullmann, Simon Schmitt, Anna Bujanow, Franziska Zientek, Konstantin Messerschmidt, André Pampel, Amira-Philine Büttner, Andreas Schildan, Osama Sabri, Kirsten Müller-Vahl, Henryk Barthel, Harald E. Möller
Target audience:
Neuroscientists, Medical researchers
Period of validity:
N/A
Date of approval:
2023
Date of changes:
N/A
Year:
2022
Region / City:
Outer Solar System
Theme:
Stellar occultation, planetary rings, Solar System dynamics
Document type:
Research article
Author:
Pablo Santos-Sanz, Altair Gomes Júnior, Bruno Morgado, Bryan Holler, John Stansberry, Heidi Hammel, Jose Luis Ortiz, Bruno Sicardy, Nicolás Morales, Josselin Desmars, Noemí Pinilla-Alonso, Richard French, Zhong-Yi Lin, Estela Fernández-Valenzuela, Mónica Vara-Lubiano, Mike Kretlow, Damya Souami, Felipe Braga-Ribas, Julio Camargo, Gustavo Benedetti-Rossi, Flavia Rommel, Rene Duffard, Marcelo Assafin, Rodrigo Leiva
Target Audience:
Astronomers, researchers in planetary science
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Religion:
Bahá’í Faith
Genre:
Devotional literature
Type of document:
Prayer collection
Authors:
Bahá’u’lláh; the Báb; ‘Abdu’l-Bahá
Compiler / editorial authority:
Bahá’í community publications
Language:
English
Core sections:
Obligatory Prayers; General Prayers; Occasional Prayers; Special Tablets
Key topics:
worship; devotion; spiritual growth; unity; healing; teaching the Faith
Included prayers:
Short Obligatory Prayer; Medium Obligatory Prayer; Long Obligatory Prayer
Associated places mentioned:
Bahjí, ‘Akká
Intended audience:
adherents of the Bahá’í Faith and participants in devotional practice
Year:
2026
Region / City:
Not specified
Theme:
Christian Metaphysics, Philosophy of Religion, Theology
Document Type:
Academic Article
Institution:
Not specified
Author:
Not specified
Target Audience:
Scholars of Theology and Philosophy
Period of Validity:
Not applicable
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Type of Document:
Supplementary Material
Authors:
Jia Yang, Kexuan Chen, Junyu Zhang, Yingzi Ma, Meiling Chen, Heng Shao, Xing Zhang, Defang Fan, Zhengbo Wang, Zhenglong Sun, Jiaojian Wang
Target Audience:
Neuroscientists, Cognitive Scientists
Research Focus:
Spatial cognition, mental rotation, neurotransmitter distribution
Methods:
Neuroimaging, transcriptomic mapping, statistical correlation analysis
Figures:
S1–S5
Tables:
S1–S3
Statistical Analysis:
Pearson correlation, two-sample t-tests, Bonferroni correction
Gender Differences:
Included in demographic analysis
Significance Threshold:
p < 0.05
Note:
Year
Document type:
Product Information
Organ / institution:
European Medicines Agency
Target audience:
Healthcare professionals, patients
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical product submission
Document type:
Application for listing
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target audience:
Health professionals, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
1 April 2014
Note:
Year
Organization / Institution:
NHS Scotland
Author:
Dr Laura Ryan, Dr John McAnaw, Mr Jim Miller
Target Audience:
Qualified health professionals within NHS Scotland
Changes History:
Eligibility age extended, new conditions added, clarifications made
Clinical Situation:
Acute uncomplicated urinary tract infection (UTI) in non-pregnant females aged 16 years and over.
Year:
2022
Region / City:
Australia
Topic:
Oncology / Hematology
Document Type:
Submission Report
Organ / Institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Celgene Pty Limited
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Ongoing
Approval Date:
8 April 2022
Amendment Date:
Not specified
Year:
2017
Region / city:
Australia
Topic:
Treatment of moderate to severe plaque psoriasis
Document type:
Resubmission for PBS listing
Authority:
Therapeutic Goods Administration (TGA)
Author:
Celgene Pty Ltd
Target audience:
Healthcare professionals, dermatologists, general physicians
Period of validity:
Ongoing
Approval date:
2017
Date of amendments:
2017
Year:
2026
Region / City:
Europe
Subject:
Product Information
Document Type:
Summary of Product Characteristics
Organization / Institution:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of Validity:
Ongoing
Approval Date:
2026
Date of Changes:
2026
Year:
2025
Region / City:
England
Topic:
Emergency contraception
Document type:
Patient Group Direction (PGD)
Organization / Institution:
NHS England
Author:
Dr Cindy Farmer, Michelle Jenkins, Vicky Garner, Gail Rowley, Julia Hogan, Kate Devonport, Chetna Parmar, Helen Donovan, Carmel Lloyd, Clare Livingstone, Kirsty Armstrong, Dipti Patel, Emma Anderson, Dr Kathy French, Dr Sarah Pillai, Alison Crompton, Andrea Smith, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins
Target audience:
Pharmacists, Pharmacy Technicians
Effective period:
June 2025 - February 2026
Approval date:
November 2022
Review date:
September 2025
Expiry date:
February 28, 2026
Year:
2023
Region / city:
Europe
Theme:
Pharmaceutical, HIV Treatment
Document Type:
Summary of Product Characteristics
Organization / Institution:
European Medicines Agency (EMA)
Author:
European Medicines Agency
Target audience:
Healthcare professionals, doctors
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Name of the medicinal product:
Miraba-S Tablets
Active substances:
Mirabegron (Extended-Release) 25 mg; Solifenacin succinate 5 mg
Pharmaceutical form:
Film coated tablet
Description:
Yellow coloured, round, biconvex, film coated tablet
Therapeutic indications:
Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Posology:
One tablet daily; may increase to two tablets daily after 4 to 8 weeks based on efficacy and tolerability
Dose adjustments:
Maximum once daily in severe renal impairment (CLcr 15–29 mL/min or eGFR 15–29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B); not recommended in ESRD or severe hepatic impairment
Method of administration:
Swallowed whole with water, with or without food; not chewed, divided, or crushed
Contraindications:
Hypersensitivity to mirabegron, solifenacin succinate, or any excipients
Special warnings and precautions:
Risk of increased blood pressure, urinary retention, angioedema, and interactions with CYP2D6 substrates
Drug interactions:
CYP2D6 substrates (e.g., metoprolol, desipramine, thioridazine, flecainide, propafenone); digoxin; warfarin
Fertility:
No human data available; no treatment-related effects observed in animals
Pregnancy:
No adequate studies in pregnant women
Lactation:
No information on presence in human milk or effects on breastfed child
Effects on ability to drive and use machines:
Mirabegron has negligible influence; solifenacin may cause blurred vision, somnolence, and fatigue
Undesirable effects:
Dry mouth, urinary tract infection, constipation, tachycardia, hypertension, urinary retention, angioedema
Reporting of suspected adverse reactions:
Healthcare professionals advised to report adverse reactions
Year:
2021
Region / City:
Global
Topic:
Medicine/Pharmaceuticals
Document Type:
Pharmaceutical Product Information
Organization:
N/A
Author:
N/A
Target Audience:
Healthcare Professionals
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A